S. H. Swerdlow, E. Campo, S. A. Pileri, N. L. Harris, H. Stein et al., The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood. 19 mai, vol.127, issue.20, pp.2375-90, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

M. W. Bekkenk, F. A. Geelen, P. C. Van-voorst-vader, F. Heule, M. L. Geerts et al., Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment, Blood. 15 juin, vol.95, issue.12, pp.3653-61, 2000.

P. T. Bradford, S. S. Devesa, W. F. Anderson, and J. R. Toro, Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases, Blood. 21 mai, vol.113, issue.21, pp.5064-73, 2009.

R. Willemze, H. Kerl, W. Sterry, B. E. Cerroni, L. Chimenti et al., EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer, Blood. 1 juill, vol.90, issue.1, pp.354-71, 1997.

G. Burg, W. Kempf, A. Cozzio, J. Feit, R. Willemze et al., WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects, J Cutan Pathol, vol.32, issue.10, pp.647-74, 2005.

E. Campo, S. H. Swerdlow, N. L. Harris, S. Pileri, H. Stein et al., The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood. 12 mai, vol.117, pp.5019-5051, 2011.

A. Fauconneau, A. Pham-ledard, D. Cappellen, E. Frison, M. Prochazkova-carlotti et al., Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases, Br J Dermatol. juin, vol.172, issue.6, pp.1547-54, 2015.

W. Kempf, A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders, Semin Diagn Pathol. janv, vol.34, issue.1, pp.22-35, 2017.

W. Kempf, K. Kerl, and C. Mitteldorf, Cutaneous CD30-positive T-cell lymphoproliferative disordersclinical and histopathologic features, differential diagnosis, and treatment, Semin Cutan Med Surg. mars, vol.37, issue.1, pp.24-33, 2018.

I. Wieser, M. T. Tetzlaff, C. A. Torres-cabala, and M. Duvic, Primary cutaneous CD30(+) lymphoproliferative disorders, J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. août, vol.14, issue.8, pp.767-82, 2016.

W. L. Macaulay, Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant, Arch Dermatol. janv, vol.97, issue.1, pp.23-30, 1968.

M. E. Kadin, Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncol Williston Park N, vol.23, pp.1158-64, 2009.

I. Wieser, C. W. Oh, R. Talpur, and M. Duvic, Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients, J Am Acad Dermatol. janv, vol.74, issue.1, pp.59-67, 2016.

W. Kempf, D. V. Kazakov, L. Schärer, A. Rütten, T. Mentzel et al., Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas, Am J Surg Pathol. janv, vol.37, issue.1, pp.1-13, 2013.

J. J. Scarisbrick, A. V. Evans, A. J. Woolford, M. M. Black, R. et al., Regional lymphomatoid papulosis: a report of four cases, Br J Dermatol. déc, vol.141, issue.6, pp.1125-1133, 1999.

R. M. Pujol, M. Muret, P. Bergua, R. Bordes, and A. Alomar, Report of two cases and review of the literature, Dermatol Basel Switz, vol.210, issue.1, pp.53-60, 2005.

E. Shabrawi-caelen, L. Kerl, H. Cerroni, and L. , Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C, Arch Dermatol. avr, vol.140, issue.4, pp.441-448, 2004.

L. J. Karai, M. E. Kadin, E. D. Hsi, J. C. Sluzevich, R. P. Ketterling et al., Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis, Am J Surg Pathol. août, vol.37, issue.8, pp.1173-81, 2013.

S. Kartan, W. T. Johnson, K. Sokol, O. Alpdogan, A. A. Gru et al., The spectrum of CD30+ T cell lymphoproliferative disorders in the skin, Chin Clin Oncol, vol.8, issue.9, 2019.

W. Kempf, K. Pfaltz, M. H. Vermeer, A. Cozzio, P. L. Ortiz-romero et al., ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma, Blood, vol.118, issue.15, pp.4024-4059, 2011.

M. Duvic, M. T. Tetzlaff, P. Gangar, A. L. Clos, D. Sui et al., Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, issue.32, pp.3759-65, 2015.

N. Cordel, B. Tressières, D. 'incan, M. Machet, L. Grange et al., Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis, The Oncologist. janv, vol.21, issue.1, pp.76-83, 2016.

M. E. Kadin and C. Carpenter, Systemic and primary cutaneous anaplastic large cell lymphomas, Semin Hematol. juill, vol.40, issue.3, pp.244-56, 2003.

B. Vergier, M. Beylot-barry, K. Pulford, P. Michel, J. Bosq et al., Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases, Am J Surg Pathol, vol.22, issue.10, pp.1192-202, 1998.

H. L. Liu, R. T. Hoppe, S. Kohler, J. D. Harvell, S. Reddy et al., CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, J Am Acad Dermatol. déc, vol.49, issue.6, pp.1049-58, 2003.

M. F. Benner and R. Willemze, Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma, Arch Dermatol. déc, vol.145, issue.12, pp.1399-404, 2009.

D. K. Woo, C. R. Jones, M. N. Vanoli-storz, S. Kohler, S. Reddy et al., Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome, Arch Dermatol. juin, vol.145, issue.6, pp.667-74, 2009.

N. Booken, S. Goerdt, and C. Klemke, Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry, J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. mai, vol.10, issue.5, pp.331-340, 2012.

R. L. Kerschmann, T. G. Berger, L. M. Weiss, B. G. Herndier, K. M. Abrahms et al., Cutaneous presentations of lymphoma in human immunodeficiency virus disease. Predominance of T cell lineage, Arch Dermatol, vol.131, issue.11, pp.1281-1289, 1995.

D. Seçkin, S. Barete, S. Euvrard, C. Francès, J. Kanitakis et al., Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. août, vol.13, issue.8, pp.2146-53, 2013.

H. Yurtsever, W. Kempf, and R. H. Laeng, Posttransplant CD30+ anaplastic large cell lymphoma with skin and lymph node involvement, Dermatol Basel Switz, vol.207, issue.1, pp.107-117, 2003.

M. Beylot-barry, B. Vergier, B. Masquelier, M. Bagot, P. Joly et al., The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 cases, Am J Surg Pathol, vol.23, issue.10, pp.1208-1224, 1999.

D. Papathemeli, R. Gräfe, U. Hildebrandt, U. K. Zettl, and J. Ulrich, Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod, Mult Scler Houndmills Basingstoke Engl, vol.22, issue.14, pp.1888-90, 2016.

E. Cesbron, J. Monfort, C. Giannesini, P. Duriez, P. Moguelet et al.,

, Ann Dermatol Venereol. juill, vol.145, issue.6-7, pp.433-441, 2018.

C. J. Hruska, R. J. Bertoli, Y. D. Young, P. H. Burkhart, and P. B. Googe, Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab, JAAD Case Rep. mars, vol.1, issue.2, pp.56-65, 2015.

A. Tournadre, D. 'incan, M. Dubost, J. J. Franck, F. Déchelotte et al., Cutaneous lymphoma associated with Epstein-Barr virus infection in 2 patients treated with methotrexate, Mayo Clin Proc. août, vol.76, issue.8, pp.845-853, 2001.

W. Kempf, M. E. Kadin, A. M. Dvorak, C. C. Lord, G. Burg et al., Endogenous retroviral elements, but not exogenous retroviruses, are detected in CD30-positive lymphoproliferative disorders of the skin, Carcinogenesis. févr, vol.24, issue.2, pp.301-307, 2003.

I. Anagnostopoulos, M. Hummel, P. Kaudewitz, H. Herbst, O. Braun-falco et al., Detection of HTLV-I proviral sequences in CD30-positive large cell cutaneous T-cell lymphomas, Am J Pathol. déc, vol.137, issue.6, pp.1317-1339, 1990.

M. S. Van-kester, C. P. Tensen, M. H. Vermeer, R. Dijkman, A. A. Mulder et al., Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators, J Invest Dermatol. févr, vol.130, issue.2, pp.563-75, 2010.

B. Homey, H. Alenius, A. Müller, H. Soto, E. P. Bowman et al., CCL27-CCR10 interactions regulate T cell-mediated skin inflammation, Nat Med. févr, vol.8, issue.2, pp.157-65, 2002.

P. Schaerli, L. Ebert, K. Willimann, A. Blaser, R. S. Roos et al., A skin-selective homing mechanism for human immune surveillance T cells, J Exp Med. 3 mai, vol.199, issue.9, pp.1265-75, 2004.

O. Zoi-toli, M. H. Vermeer, D. Vries, E. , V. Beek et al., Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL, Br J Dermatol. août, vol.143, issue.2, pp.313-322, 2000.

W. P. Schiemann, W. M. Pfeifer, E. Levi, M. E. Kadin, and H. F. Lodish, A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma, Blood, vol.94, issue.8, pp.2854-61, 1999.

M. Watanabe, Y. Ogawa, K. Ito, M. Higashihara, M. E. Kadin et al., AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells, Am J Pathol. août, vol.163, issue.2, pp.633-674, 2003.

D. A. Wada, M. E. Law, E. D. Hsi, D. J. Dicaudo, L. Ma et al., Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies, Mod Pathol Off J U S Can Acad Pathol Inc. avr, vol.24, issue.4, pp.596-605, 2011.

I. Hellier, O. Dereure, M. Segondy, B. Guillot, P. Baldet et al., Unlikely role of Epstein-Barr virus in the pathogenesis of primary cutaneous CD30+ anaplastic large cell lymphoma, Eur J Dermatol EJD. juin, vol.11, issue.3, pp.203-211, 2001.

Y. C. Kim, W. I. Yang, M. Lee, S. N. Kim, K. H. Cho et al., Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea, Int J Dermatol, vol.45, issue.11, pp.1312-1318, 2006.

H. Stein, H. D. Foss, H. Dürkop, T. Marafioti, G. Delsol et al., CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features, Blood. 1 déc, vol.96, issue.12, pp.3681-95, 2000.

Y. Kong, B. Dai, J. Kong, H. Lu, and D. Shi, Neutrophil/eosinophil-rich type of primary cutaneous anaplastic large cell lymphoma: a clinicopathological, immunophenotypic and molecular study of nine cases, Histopathology. août, vol.55, issue.2, pp.189-96, 2009.

W. Kempf, D. V. Kazakov, B. E. Paredes, H. R. Laeng, G. Palmedo et al., Primary cutaneous anaplastic large cell lymphoma with angioinvasive features and cytotoxic phenotype: a rare lymphoma variant within the spectrum of CD30+ lymphoproliferative disorders, Dermatol Basel Switz, vol.227, issue.4, pp.346-52, 2013.

R. C. Beljaards, C. J. Meijer, E. Scheffer, J. Toonstra, W. A. Van-vloten et al., Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients, Am J Pathol. déc, vol.135, issue.6, pp.1169-78, 1989.

M. Ansari, F. A. Ardalan, M. Najafi, A. Goodarzi, and A. Ghanadan, Primary Cutaneous LymphomaAssociated Pseudoepitheliomatous Hyperplasia Masquerading as Squamous Cell Carcinoma in a Young Adult, p.4

K. P. Mann, B. Hall, H. Kamino, M. J. Borowitz, and H. Ratech, Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma, Am J Surg Pathol. avr, vol.19, issue.4, pp.407-423, 1995.

C. Massone, L. El-shabrawi-caelen, H. Kerl, and L. Cerroni, The morphologic spectrum of primary cutaneous anaplastic large T-cell lymphoma: a histopathologic study on 66 biopsy specimens from 47 patients with report of rare variants, J Cutan Pathol. janv, vol.35, issue.1, pp.46-53, 2008.

J. Wang, N. C. Sun, Y. Nozawa, D. A. Arber, P. Chu et al., Histological and immunohistochemical characterization of extranodal diffuse large-cell lymphomas with prominent spindle cell features, Histopathology, vol.39, issue.5, pp.476-81, 2001.

K. Bassett, N. Stutz, M. L. Stenstrom, G. S. Wood, and M. G. Fleming, Primary cutaneous sarcomatoid anaplastic large-cell lymphoma, Am J Dermatopathol. mai, vol.34, issue.3, pp.301-305, 2012.

H. Chen, J. Xiong, N. Sheng, W. Zong, Y. Wang et al., Primary Cutaneous Sarcomatoid Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma With Linear Distributional Lesions, Am J Dermatopathol, vol.39, issue.11, pp.863-869, 2017.

J. Lin and J. Lee, Primary cutaneous CD30 anaplastic large cell lymphoma with keratoacanthoma-like pseudocarcinomatous hyperplasia and marked eosinophilia and neutrophilia, J Cutan Pathol. juill, vol.31, issue.6, pp.458-61, 2004.

G. Vasmatzis, S. H. Johnson, R. A. Knudson, R. P. Ketterling, E. Braggio et al., Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas, Blood. 13 sept, vol.120, issue.11, pp.2280-2289, 2012.

A. Schrader, Y. Chung, P. M. Jansen, K. Szuhai, B. Torres et al., No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoproliferative disorders with aggressive clinical course, Blood, vol.07, issue.1, pp.141-144, 2016.

G. Macgrogan, B. Vergier, P. Dubus, M. Beylot-barry, G. Belleannee et al., CD30-positive cutaneous large cell lymphomas. A comparative study of clinicopathologic and molecular features of 16 cases, Am J Clin Pathol. avr, vol.105, issue.4, pp.440-50, 1996.

N. Shikama, Local radiation for cutaneous T-cell lymphoma other than mycosis fungoides and Sézary syndrome, Chin Clin Oncol. 19 juill, 2018.

E. Geissinger, P. Sadler, S. Roth, T. Grieb, B. Puppe et al., Disturbed expression of the Tcell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations, Haematologica, vol.95, issue.10, pp.1697-704, 2010.

I. Oschlies, J. Lisfeld, L. Lamant, A. Nakazawa, E. Amore et al., ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study, Haematologica. janv, vol.98, issue.1, pp.50-56, 2013.

A. Fornari, R. Piva, R. Chiarle, D. Novero, and G. Inghirami, Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?, Hematol Oncol. déc, vol.27, issue.4, pp.161-70, 2009.

A. L. Feldman, M. Law, E. D. Remstein, W. R. Macon, L. A. Erickson et al., Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas, Leukemia. mars, vol.23, issue.3, pp.574-80, 2009.

J. F. Decoteau, J. R. Butmarc, M. C. Kinney, and M. E. Kadin, The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin, Blood. 15 avr, vol.87, issue.8, pp.3437-3478, 1996.

G. Li, K. E. Salhany, A. H. Rook, and S. R. Lessin, The pathogenesis of large cell transformation in cutaneous T-cell lymphoma is not associated with t(2;5)(p23;q35) chromosomal translocation, J Cutan Pathol. août, vol.24, issue.7, pp.403-411, 1997.

K. J. Savage, N. L. Harris, J. M. Vose, F. Ullrich, E. S. Jaffe et al., ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project, Blood. 15 juin, vol.111, issue.12, pp.5496-504, 2008.

R. Y. Bai, P. Dieter, C. Peschel, S. W. Morris, and J. Duyster, Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity, Mol Cell Biol. déc, vol.18, issue.12, pp.6951-61, 1998.

P. Castellar, E. R. Jaffe, E. S. Said, J. W. Swerdlow, S. H. Ketterling et al., ALKnegative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes, Blood. 28 août, vol.124, issue.9, pp.1473-80, 2014.

M. E. Kadin, J. L. Pinkus, G. S. Pinkus, I. H. Duran, C. E. Fuller et al., Primary Cutaneous ALCL With Phosphorylated/Activated Cytoplasmic ALK and Novel Phenotype: EMA/MUC1+, Cutaneous Lymphocyte Antigen Negative, Am J Surg Pathol. sept, vol.32, issue.9, pp.1421-1427, 2008.

L. Quintanilla-martinez, P. M. Jansen, M. C. Kinney, S. H. Swerdlow, and R. Willemze, Non-Mycosis Fungoides Cutaneous T-Cell Lymphomas, Am J Clin Pathol. 1 avr, vol.139, issue.4, pp.491-514, 2013.

R. Willemze, L. Cerroni, W. Kempf, B. E. Facchetti, F. Swerdlow et al., The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas, Blood. 11 janv, 2019.

A. L. Feldman, A. Dogan, D. I. Smith, M. E. Law, S. M. Ansell et al., Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing, Blood. 20 janv, vol.117, issue.3, pp.915-924, 2011.

B. Vergier, A. De-muret, M. Beylot-barry, L. Vaillant, D. Ekouevi et al., Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas, Blood. 1 avr, vol.95, issue.7, pp.2212-2220, 2000.

E. Diamandidou, M. Colome-grimmer, L. Fayad, M. Duvic, and R. Kurzrock, Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis, Blood. 15 août, vol.92, issue.4, pp.1150-1159, 1998.

M. E. Kadin, L. C. Hughey, and G. S. Wood, Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium, J Am Acad Dermatol. févr, vol.70, issue.2, pp.374-380, 2014.

M. F. Benner, P. M. Jansen, M. H. Vermeer, and R. Willemze, Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases, Blood. 16 févr, vol.119, issue.7, pp.1643-1652, 2012.

F. Grange, G. Hedelin, P. Joly, M. Beylot-barry, D. 'incan et al., Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas, Blood. 1 juin, vol.93, issue.11, pp.3637-3679, 1999.

E. Laharanne, E. Chevret, Y. Idrissi, C. Gentil, M. Longy et al., CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma, Mod Pathol Off J U S Can Acad Pathol Inc. avr, vol.23, issue.4, pp.547-58, 2010.

E. Laharanne, N. Oumouhou, F. Bonnet, M. Carlotti, C. Gentil et al., Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes, J Invest Dermatol. juin, vol.130, issue.6, pp.1707-1725, 2010.

M. F. Benner, E. Ballabio, M. S. Van-kester, N. J. Saunders, M. H. Vermeer et al., Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor-stage mycosis fungoides, Exp Dermatol. août, vol.21, issue.8, pp.632-636, 2012.

A. Pham-ledard, M. Prochazkova-carlotti, E. Laharanne, B. Vergier, T. Jouary et al., IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases, J Invest Dermatol. mars, vol.130, issue.3, pp.816-841, 2010.

A. R. Nicolae-cristea, M. F. Benner, W. H. Zoutman, R. Van-eijk, P. M. Jansen et al., Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30-positive lymphoproliferative disease, Br J Dermatol. mars, vol.172, issue.3, pp.784-792, 2015.

M. Battistella, A. Janin, F. Jean-louis, C. Collomb, C. Leboeuf et al., KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma, Br J Dermatol. août, vol.175, issue.2, pp.325-358, 2016.

H. Suga, M. Sugaya, T. Miyagaki, H. Ohmatsu, H. Fujita et al., Differential patterns of CXCR3, CCR3, and CCR10 expression in mycosis fungoides, Sezary syndrome and CD30(+) lymphoproliferative disorders: immunohistochemical study of 43 samples, J Dermatol Sci, vol.64, issue.2, pp.142-146, 2011.

C. Droc, H. D. Cualing, and M. E. Kadin, Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin, Cancer Control J Moffitt Cancer Cent. avr, vol.14, issue.2, pp.124-156, 2007.

H. S. Zackheim, C. Jones, P. E. Leboit, M. Kashani-sabet, T. H. Mccalmont et al., Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality, J Am Acad Dermatol, vol.49, issue.4, pp.620-623, 2003.

J. H. Kunishige, H. Mcdonald, G. Alvarez, M. Johnson, V. Prieto et al., Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients, Clin Exp Dermatol. juill, vol.34, issue.5, pp.576-81, 2009.

S. Chaganti, E. M. Heath, W. Bergler, M. Kuo, M. Buettner et al., Epstein-Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence, Blood. 18 juin, vol.113, issue.25, pp.6372-81, 2009.

J. I. Cohen, Epstein-Barr virus infection, N Engl J Med. 17 août, vol.343, issue.7, pp.481-92, 2000.

A. Nicolae, S. Pittaluga, S. Abdullah, S. M. Steinberg, T. A. Pham et al., EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment, Blood. 13 août, vol.126, issue.7, pp.863-72, 2015.

J. L. Crombie and A. S. Lacasce, Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders, Front Oncol, vol.9, p.109, 2019.

A. L. Katzenstein, C. B. Carrington, and A. A. Liebow, Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases, Cancer. janv, vol.43, issue.1, pp.360-73, 1979.

H. De-boysson and L. Geffray,

, Rev Med Interne. juin, vol.34, issue.6, pp.349-57, 2013.

S. D. Dojcinov, G. Venkataraman, M. Raffeld, S. Pittaluga, and E. S. Jaffe, EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression, Am J Surg Pathol. mars, vol.34, issue.3, pp.405-422, 2010.

G. L. Smith, M. Duvic, Z. A. Yehia, P. Allen, N. Garg et al., Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma, Adv Radiat Oncol. sept, vol.2, issue.3, pp.363-372, 2017.

R. C. Melchers, R. Willemze, L. A. Daniëls, K. J. Neelis, M. W. Bekkenk et al., Recommendations for the Optimal Radiation Dose in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma: A Report of the Dutch Cutaneous Lymphoma Group, Int J Radiat Oncol Biol Phys, vol.01, issue.5, pp.1279-85, 2017.

L. Million, E. J. Yi, F. Wu, V. Eyben, R. Campbell et al., Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience, Int J Radiat Oncol Biol Phys, vol.01, issue.5, pp.1454-1463, 2016.

H. M. Prince, Y. H. Kim, S. M. Horwitz, R. Dummer, J. Scarisbrick et al., Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial, Lancet Lond Engl. 05, vol.390, pp.555-66, 2017.

R. Stranzenbach, E. Dippel, M. Schlaak, and R. Stadler, Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature, Br J Dermatol, vol.177, issue.6, pp.1503-1512, 2017.

T. H. Enos, L. S. Feigenbaum, and H. W. Wickless, Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data, Int J Dermatol. déc, vol.56, issue.12, pp.1400-1405, 2017.

Y. H. Kim, M. Tavallaee, U. Sundram, K. A. Salva, G. S. Wood et al., Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, issue.32, pp.3750-3758, 2015.

M. E. Kadin, E. Levi, and W. Kempf, Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand, Ann N Y Acad Sci. sept, vol.941, pp.59-68, 2001.

H. Stein, D. Y. Mason, J. Gerdes, N. O'connor, J. Wainscoat et al., The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells, Blood. oct, vol.66, issue.4, pp.848-58, 1985.

C. A. Smith, H. J. Gruss, T. Davis, D. Anderson, F. T. Baker et al., CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF, Cell. 2 juill, vol.73, issue.7, pp.1349-60, 1993.

M. Welborn and M. Duvic, Antibody-Based Therapies for Cutaneous T-Cell Lymphoma, Am J Clin Dermatol, issue.15, 2018.

D. Sur,

W. Gorczyca, P. Tsang, Z. Liu, C. Wu, H. Dong et al., CD30-positive T-cell lymphomas co-expressing CD15: An immunohistochemical analysis, Int J Oncol [Internet]. 1 févr, 2003.

D. Sur,

B. Werner, C. Massone, H. Kerl, and L. Cerroni, Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin, J Cutan Pathol. déc, vol.35, issue.12, pp.1100-1107, 2008.

W. Kempf, CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators, J Cutan Pathol. févr, vol.33, issue.1, pp.58-70, 2006.

, Annexe II : Le cluster de différenciation CD30+

C. En, que l'équipe de Stein a découvert l'antigène Ki-1 ou CD30 comme un récepteur cytokinique impliqué dans la prolifération tumorale des cellules CD30+, p.105, 1982.

C. Le, aussi appelé TNFRSF8 ou antigène Ki-1, est un marqueur d'activation des lymphocytes T

, Ce récepteur transmembranaire est une glycoprotéine de 120kDa appartenant à la superfamille des récepteurs au Tumor Necrosis Factor (TNF) (107)

, On sait actuellement qu'il est impliqué dans l'activation de l'apoptose, la régulation des lymphocytes T CD4+ (108) et qu'il limite la prolifération des lymphocytes T CD8+ autoréactifs avec un rôle

, On le retrouve dans d'autres lymphomes primitivement cutanés (PLy et les TMF) et systémiques (les cellules de Reed Sternberg des lymphomes de Hodgkin expriment en plus le CD15

, Hormis les lymphomes, il est exprimé par les cellules des carcinomes embryonnaires, ce qui permet leur distinction avec les seminomes qui ne l

. Enfin, le retrouve dans des pathologies plus bénignes comme les piqures d'arthropodes, les nodules d'Orf, les nodules scabieux, les leishmanioses, les syphilis, les lésions cutanées herpétiques HSV et VZV? (110, vol.111

, Cet antigène CD30+ est actuellement la cible de traitement ciblé comme le Brentuximab Vedotin (8), p.66

I. Annexe, Stadification TNM Réponse après troisième ligne : Réponse complète (RC) : Réponse partielle (RP) : Progression ou stable (P) : Quatrième ligne ? : Si oui : Car non réponse (RP ou P) à la précédente ligne : oui non Car rechute après rémission complète : oui non Si oui : Date de rechute :???????

, Rechute cutanée : oui / non. Si oui, localisation : ?????. Rechute ganglionnaire : oui / non. Si oui, localisation : ????

, Réponse partielle (RP) : Progression ou stable

. Serment-d'hippocrate,

, En présence des Maîtres de cette FACULTE et de mes chers CONDISCIPLES, je promets et je jure d'être fidèle aux lois de l'Honneur et de la Probité dans l

, Je donnerai mes soins gratuits à l'indigent et je n'exigerai jamais un salaire au-dessus de mon travail

, Admis dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés et mon état ne servira pas à corrompre les moeurs ni à favoriser le crime

, Respectueux et reconnaissant envers mes MAÎTRES, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères

, Que les HOMMES m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couvert d'OPPROBRE et méprisé de mes confrères si j'y manque